Document Classification

Section Type: METHODS

Text: In this final analysis of a phase 3, randomised, multicentre, double-blind study, patients aged 6 months to 17 years with a documented malignancy who were scheduled to receive either moderately or highly emetogenic chemotherapy were randomly assigned with an interactive voice response system to an age-based and weight-based blinded regimen of aprepitant (125 mg for ages 12-17 years ; 30 mg/kg up to 125 mg for ages 6 months to < 12 years) plus ondansetron on day 1, followed by aprepitant (80 mg for ages 12-17 years ; 20 mg/kg up to 80 mg for ages 6 months to < 12 years) on days 2 and 3, or placebo plus ondansetron on day 1 followed by placebo on days 2 and 3 ; addition of dexamethasone was allowed.